Sanofi said the bulk of the investment will double capacity of monoclonal antibody production, which are key in developing an array of pharmaceuticals, at its Vitry-sur-Seine site.
![](https://immunet.online/wp-content/uploads/2024/05/medium-9CvIRz.jpeg)
Sanofi said the bulk of the investment will double capacity of monoclonal antibody production, which are key in developing an array of pharmaceuticals, at its Vitry-sur-Seine site.